AzTrials
AzTrials

PeriodontitisPDTV2NCT03270254

Photodynamic Therapy Plus Root Debridement in Gum Disease Treatment V2

A study testing light activated dye photodynamic therapy (PDT) in people with Periodontitis, run by Sheffield Teaching Hospitals NHS Foundation Trust at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Gum disease is a common disease, which affects 45% of the UK adult dentate population. It is caused by bacteria in dental plaque, which produces inflammation and a deepening of the natural crevice between the gum and the tooth surface. Read more about this study

Who is it for?
Ages 30 years and older
Conditions the study is for
Periodontitis
What is being tested?
light activated dye photodynamic therapy (PDT)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
31 participants
Where
1 siteUnited Kingdom
Study dates
13 Oct 2017to 19 Sep 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients ≥ 30 years old
  • Presence of at least 20 remaining teeth
  • Patients diagnosed with moderate to severe chronic periodontitis, according to Armitage 1999 classification
  • Have undergone a minimum of one cycle of full mouth nonsurgical root surface debridement.
  • A minimum of 8 residual periodontal pockets (≥4mm) per patient and a maximum of 24. Amongst these, at least one site per half mouth must exhibit pocket depths of ≥ 6 mm.
  • Pockets distribution should allow for split mouth design using sextants in a diagonal orientation.
Show all 9Show fewer
  • Received no active periodontal treatment for the last three months.
  • Full mouth plaque score and full mouth bleeding score ≤ 30%.
  • Sites in the other half of the mouth to be separated by one or more teeth (avoids photosensitising agent affecting the other half).

Who cannot join

  • Patients with systemic diseases that may alter the response to treatment and healing in periodontal diseases.
  • Pregnancy and lactation.
  • The use of systemic or local antibiotic in the past three months.
  • The need for antibiotic prophylaxis before periodontal treatment.
  • Use of antimicrobial mouth rinses in the preceding two months.
  • The use of any pharmacological agents that could influence the study outcome or inflammatory indicators (e.g. patients currently on photosensitizing medications).
Show all 12Show fewer
  • Confirmed or suspected allergy or hypersensitivity to methylene blue.
  • Confirmed or suspected allergy or hypersensitivity to chlorhexidine.
  • Confirmed or suspected allergy or hypersensitivity to polymethyl methacrylate (PMMA).
  • Patients with severe glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • Inability to perform proper oral hygiene due to physical impairment.
  • Patients unable to consent for themselves.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Sheffield Teaching Hospitals NHS Trust

    Sheffield, South Yorkshire, S10 2JF

Other trials in United Kingdom

About this study

Official title: A Split-mouth Randomised Controlled Clinical Trial of Photodynamic Therapy (PDT) as Adjunctive Therapy to Root Surface Debridement (RSD), Compared to RSD Alone in the Treatment of Residual Periodontal Pockets in Patients With Chronic Periodontitis

Gum disease is a common disease, which affects 45% of the UK adult dentate population. It is caused by bacteria in dental plaque, which produces inflammation and a deepening of the natural crevice between the gum and the tooth surface. A crevice of 3mm is considered to be within the normal range, but anything ≥4mm is considered to be abnormal and is called a "pocket". Standard treatment of gum disease is mechanical cleaning aimed at removing bacteria off the root surfaces of the teeth. For most teeth, in the majority of patients, this can be achieved by root surface debridement (RSD), which involves passing instruments into the gum pockets to clean the roots. Previous studies have shown that the outcome of treatment is less effective when the pockets are deeper, or where there is bone or root anatomy which makes access for RSD difficult. In such instances additional approaches, such as repeating RSD, surgical access, or the additional use of antibiotics are considered. This clinical study will investigate the benefits and drawbacks of using a light source and dye (photodynamic therapy - PDT) as an additional treatment compared to the standard treatment of RSD alone. Patients with chronic gum problems who have undergone 1 cycle of RSD, but have residual pockets will be invited to join the study. All residual pockets will be treated with the conventional treatment of RSD. Following a random allocation process the residual pockets in half the mouth will receive additional treatment with PDT at the same appointment. Patients will be followed up for 3 months to evaluate the clinical benefits and any side effects. The aim of the study is therefore to evaluate if this localised, simple treatment can add benefit to RSD alone, thus reducing the need for antibiotics or surgery to treat residual pockets.

Read the detailed description

The study will be a single centre, examiner masked, two arm, split mouth, randomized controlled clinical trial, to evaluate the clinical effectiveness of mechanical cleaning (RSD) plus additional use of a light activated dye (photodynamic therapy-PDT) compared to mechanical cleaning alone, in the treatment of residual pockets, in patients with chronic gum disease. The null hypothesis is that there is no difference between RSD and the additional use of PDT compared to RSD alone, when treating patients with chronic gum disease. The local delivery treatment of PDT requires the low power light to be shone into the pocket for 1 minute in order to activate the dye which kills the bacteria. For this reason it is a treatment which is more suited to treating localised rather than widespread disease. Thus, patients with chronic gum problems who have had a cycle of treatment with the hygienist, but have a few residual pockets will be selected for this study. Subjects will be recruited from patients attending the hygienist following a first cycle of RSD, who have sufficient remaining disease to represent a meaningful challenge. This reflects the normal care pathway for patients, where simple approaches to treatment are followed up with more complicated therapy for any areas which fail to respond. A power calculation has shown that 29 patients are expected to be enough to see if PDT \& RSD can produce better gum health than RSD alone. However, to account for unexpected patient withdrawals, 35 patients will be recruited to this study. The staff hygienists in the department are capable of providing treatment for 60-90 patients over a 3-month period. Out of these patients those with more severe disease are likely to have residual pockets that require further cycles of RSD. Thus there is potentially a good population of patients attending Charles Clifford Dental Hospital to recruit from. All residual sites within a subject who participates in the study will be treated by mechanical cleaning. This is the standard treatment which would apply for most patients in this situation. A random allocation procedure will be used to designate sections of the mouth to receive additional treatment with the PDT. This will not be made known to the operator performing the RSD until after they have completed that aspect of treatment. This helps reduce bias as the operator will clean all sites to an equivalent standard. The split mouth approach means that the patient will act as their own control. This helps reduce the numbers of patients which need to be recruited as compared to a study with 2 parallel groups, where each group receives a different treatment. The suggested disadvantage of a split mouth design, is the fact that there may be some contamination of RSD sites only with the action of a chemical remote from the site it was originally placed in. However, in this study the chemical needs to be activated by the light, and therefore it is easier to control the activity of PDT therapy to the sites it was designated to be used in. For this reason there needs to be a gap between the section of the mouth treated by adjunctive PDT \& RSD, compared to the section of the mouth where RSD alone is the treatment. No additional appointments will be required of the patients compared to the normal protocol as they will receive the "gold standard" treatment of mechanical cleaning (RSD) in all sites. The additional requirements of the study will be the time it takes to provide treatment using PDT. This is anticipated to be between 5-15 minutes depending upon the number and distribution of sites throughout the mouth. Sample collection of bacterial plaque and gum fluid from 2 sites per patient will take an additional 5-10 minutes. The normal treatment time at this stage of treatment would be 60 minutes and this will be extended to 70-85 minutes for the study purposes. None of the additional procedures are likely to cause discomfort. The 3 month re-assessment examination will require repeat sample collection of bacterial plaque and gum fluid from 2 sites which will take an additional 5-10 minutes. Thus the standard patient reassessment appointment of 60 minutes will be extended to 65-70 minutes. The full process from recruitment of patients to writing up this student project is expected to be finished within seven to nine months.

Conditions
Periodontitis
Being tested
light activated dye photodynamic therapy (PDT)
Medical subject headings
Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • light activated dye photodynamic therapy (PDT)Device

    light activated dye photodynamic therapy-PDT to periodontal pockets

Study groups in NCT03270254
Study groupRoleWhat they receive
root surface debridement (RSD)No interventionStandard care - root surface debridement (RSD)
light activated dye (PDT)Active comparatorlight activated dye photodynamic therapy (PDT)
Receives: Device: light activated dye photodynamic therapy (PDT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pocket depth change

    The difference in mean change of probing pocket depth in millimetres between the test and control sites

    Measured: 3 months

Secondary outcomes (6)
  1. Change in clinical attachment

    The difference in mean change of clinical attachment loss in millimetres between the test and control sites.

    Measured: 3 months

  2. Bleeding on probing

    The percentage difference of bleeding on probing between tests and controls.

    Measured: 3 months

  3. Probing depths originally ≥ 6mm.

    The percentage difference of sites with probing depths originally ≥ 6mm.

    Measured: 3 months

  4. Probing depths originally ≤3mm

    The percentage increase of sites with probing depths originally ≤3mm

    Measured: 3 months

  5. Number of sites improving by ≥2mm

    The total number of sites improving by ≥2mm

    Measured: 3 months

  6. Percentage of sites improving by ≥2mm

    The percentage of sites improving by ≥2mm

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2017
  2. Study start13 Oct 2017
  3. Primary completion19 Sep 2018
  4. Study completion19 Sep 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Model description
Randomised Split mouth
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
31 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03270254
Sponsor's protocol ID
STH19404
Acronym
PDTV2
Status last verified
May 2019
First submitted
30 Aug 2017
Last updated
30 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: The research findings will probably be published in a scientific journal

Questions about this trial

What is this clinical trial studying?

A study testing light activated dye photodynamic therapy (PDT) in people with Periodontitis, run by Sheffield Teaching Hospitals NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pocket depth change (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in